| Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients (NCT05176470) | Richard Wu | 2022-07-01 |
| Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS) (NCT07376317) | Instituto do Cancer do Estado de São Paulo | 2021-12-10 |
| Sargramostim (GM-CSF) + PD-1 (NCT04703426) | Dana-Farber Cancer Institute | 2021-04-16 |
| Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer (NCT04670445) | Massachusetts General Hospital | 2021-01-23 |
| A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma (NCT04356729) | F. Stephen Hodi, MD | 2020-08-06 |
| Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors (NCT04142931) | Dr. Ronnie Shapira | 2020-02-24 |
| Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors (NCT03385486) | Taiga Biotechnologies, Inc. | 2019-06-02 |
| TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma (NCT04059224) | Universitair Ziekenhuis Brussel | 2019-01-28 |
| Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (NCT03235245) | European Organisation for Research and Treatment of Cancer - EORTC | 2018-10-30 |
| Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma (NCT03200847) | University of Colorado, Denver | 2017-10-31 |
| Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients (NCT02744209) | Mayo Clinic | 2016-04-01 |
| Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma (NCT02676869) | Immutep Australia Pty. Ltd. | 2016-04-01 |
| Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma (NCT02327390) | Case Comprehensive Cancer Center | 2015-03-17 |
| Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations (NCT02296112) | Vanderbilt-Ingram Cancer Center | 2015-01-01 |
| Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma (NCT02306850) | St. Louis University | 2015-01-01 |
| Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations (NCT02263898) | Jonsson Comprehensive Cancer Center | 2015-01-01 |
| APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery (NCT02166255) | Wake Forest University Health Sciences | 2014-12-01 |
| High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery (NCT02203604) | CINJRegulatory | 2014-11-26 |
| Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma (NCT01875653) | Lisata Therapeutics, Inc. | 2014-10-01 |
| Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma (NCT02107755) | Ohio State University Comprehensive Cancer Center | 2014-09-05 |
| Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma (NCT02073123) | NewLink Genetics Corporation | 2014-07-01 |
| Immunotherapy Study for Patients With Stage IV Melanoma (NCT02054520) | NewLink Genetics Corporation | 2014-06-01 |
| Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic (NCT02094872) | Yale University | 2014-05-01 |
| Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery (NCT01835184) | National Cancer Institute (NCI) | 2013-05-01 |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations (NCT01726738) | UNC Lineberger Comprehensive Cancer Center | 2013-04-04 |
| Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma (NCT01703507) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-11-09 |
| Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery (NCT01748747) | Mayo Clinic | 2012-10-01 |
| FDG-PET in Advanced Melanoma (NCT02236546) | Vanderbilt-Ingram Cancer Center | 2012-05-01 |
| Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma (NCT02507076) | Albert Einstein College of Medicine | 2012-04-01 |
| Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma (NCT01339663) | Fred Hutchinson Cancer Center | 2012-03-01 |
| Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib (NCT01519427) | National Cancer Institute (NCI) | 2012-01-01 |
| Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma (NCT00979693) | Multidisciplinary Association for Psychedelic Studies | 2012-01-01 |
| Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery (NCT01533948) | Roswell Park Cancer Institute | 2012-01-01 |
| Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma (NCT01316692) | Vanderbilt-Ingram Cancer Center | 2011-10-01 |
| Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma (NCT01376713) | Medical University of Vienna | 2011-06-01 |
| Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery (NCT01328535) | Mayo Clinic | 2011-01-01 |
| Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma (NCT01026051) | Mannkind Corporation | 2010-10-01 |
| Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma (NCT01120275) | National Cancer Institute (NCI) | 2010-10-01 |
| Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV (NCT01166126) | National Cancer Institute (NCI) | 2010-10-01 |
| RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery (NCT01216787) | National Cancer Institute (NCI) | 2010-09-01 |
| An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma (NCT01136967) | Eisai Inc. | 2010-08-01 |
| Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma (NCT01107665) | University of California, Irvine | 2010-08-01 |
| Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma (NCT01127451) | Eisai Inc. | 2010-06-22 |
| Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma (NCT01106235) | Fred Hutchinson Cancer Center | 2010-04-01 |
| E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma (NCT01133977) | Eisai Inc. | 2010-04-01 |
| Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma (NCT01103635) | Abramson Cancer Center at Penn Medicine | 2010-02-01 |
| Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer (NCT01037790) | Abramson Cancer Center at Penn Medicine | 2009-10-01 |
| Dinaciclib in Treating Patients With Stage III-IV Melanoma (NCT01026324) | National Cancer Institute (NCI) | 2009-09-01 |
| LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma (NCT01010984) | Robert C. Martin | 2009-09-01 |
| Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma (NCT00945269) | Fred Hutchinson Cancer Center | 2009-07-01 |
| Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma (NCT00871481) | Fred Hutchinson Cancer Center | 2009-02-01 |
| Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma (NCT00726739) | Masonic Cancer Center, University of Minnesota | 2008-06-01 |
| Viral Therapy in Treating Patients With Metastatic Melanoma (NCT00651157) | National Cancer Institute (NCI) | 2008-04-01 |
| Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma (NCT00553306) | Fred Hutchinson Cancer Center | 2007-09-01 |
| Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery (NCT00281957) | National Cancer Institute (NCI) | 2007-08-01 |
| VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (NCT00450255) | National Cancer Institute (NCI) | 2007-06-01 |
| Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers (NCT00498979) | Case Comprehensive Cancer Center | 2007-05-01 |
| Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (NCT00470470) | National Cancer Institute (NCI) | 2007-04-01 |
| Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma (NCT00438984) | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | 2006-12-01 |
| A Study of Volociximab in Metastatic Melanoma (NCT00369395) | Abbott | 2006-12-01 |
| Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma (NCT00436605) | National Cancer Institute (NCI) | 2006-12-01 |
| Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery (NCT00669019) | National Cancer Institute (NCI) | 2006-07-01 |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma (NCT01851408) | National Cancer Institute (NCI) | 2006-04-01 |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma (NCT00349206) | National Cancer Institute (NCI) | 2006-04-01 |
| AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma (NCT00243061) | National Cancer Institute (NCI) | 2006-01-01 |
| Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery (NCT00255762) | National Cancer Institute (NCI) | 2005-12-01 |
| Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma (NCT00303836) | National Cancer Institute (NCI) | 2005-11-01 |
| Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma (NCT00288041) | National Cancer Institute (NCI) | 2005-10-01 |
| Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma (NCT00121225) | National Cancer Institute (NCI) | 2005-09-01 |
| Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery (NCT00217542) | National Cancer Institute (NCI) | 2005-07-01 |
| Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery (NCT00119249) | National Cancer Institute (NCI) | 2005-06-01 |
| Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (NCT00655655) | Mayo Clinic | 2004-12-01 |
| A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma (NCT00199342) | Kyowa Kirin, Inc. | 2004-11-01 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma (NCT00089063) | National Cancer Institute (NCI) | 2004-06-01 |
| Tanespimycin in Treating Patients With Stage III-IV Melanoma (NCT00087386) | National Cancer Institute (NCI) | 2004-06-01 |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma (NCT00087373) | National Cancer Institute (NCI) | 2004-06-01 |
| Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma (NCT00085189) | University of Southern California | 2004-05-01 |
| Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma (NCT00085306) | Case Comprehensive Cancer Center | 2004-04-01 |
| Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma (NCT00082875) | National Cancer Institute (NCI) | 2004-03-01 |
| A Phase II Study of UCN-01 in Metastatic Melanoma (NCT00072189) | National Cancer Institute (NCI) | 2003-11-01 |
| Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma (NCT00072163) | National Cancer Institute (NCI) | 2003-10-01 |
| Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers (NCT00074308) | National Cancer Institute (NCI) | 2003-10-01 |
| Tipifarnib in Treating Patients With Metastatic Malignant Melanoma (NCT00060125) | National Cancer Institute (NCI) | 2003-05-01 |
| Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer (NCT00039091) | National Cancer Institute (NCI) | 2002-03-01 |
| BMS-247550 in Treating Patients With Stage IV Melanoma (NCT00036764) | National Cancer Institute (NCI) | 2002-02-01 |
| Disulfiram in Patients With Metastatic Melanoma (NCT00256230) | John P. Fruehauf | 2002-01-01 |
| Decitabine in Treating Patients With Advanced Solid Tumors (NCT00030615) | National Cancer Institute (NCI) | 2001-12-01 |
| PS-341 in Treating Patients With Metastatic Malignant Melanoma (NCT00024011) | National Cancer Institute (NCI) | 2001-07-01 |
| Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma (NCT00005949) | National Cancer Institute (NCI) | 2001-03-01 |
| Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma (NCT00006243) | National Cancer Institute (NCI) | 2000-10-01 |
| SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated (NCT00006003) | National Cancer Institute (NCI) | 2000-07-01 |
| Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma (NCT00003552) | National Heart, Lung, and Blood Institute (NHLBI) | 1999-01-01 |
| Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma (NCT00019448) | National Cancer Institute (NCI) | 1998-09-01 |
| Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma (NCT00003646) | Vical | 1998-08-01 |
| Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma (NCT00003647) | Vical | 1998-07-01 |
| flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer (NCT00019396) | National Cancer Institute (NCI) | 1998-02-01 |
| Antineoplaston Therapy in Treating Patients With Stage IV Melanoma (NCT00003509) | Burzynski Research Institute | 1996-03-27 |
| Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases (NCT02145910) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | |
| Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma (NCT00019890) | National Cancer Institute (NCI) | |